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On treatment of 3-amino-5-aryl-1H-pyrazoles 1 with dialkyl dicyanofumarates 4 
in boiling 1,2-dichloroethane, two competitive reactions occurred leading to 5-aryl-3-
cyano-2,7-dihydro-2-oxo-1H-pyrazolo[3,4-b]pyridine-4-carboxylates 10 and 4-amino-
7-arylpyrazolo[2,3-a]pyrimidine-2,3-dicarboxylates 11. In DMF at room temperature as 
well as at 100°, only compounds 10 were obtained. The formation of the major products 
of type 10 was explained via Michael addition of 1 as a C(4) nucleophile onto 4, 
followed by HCN elimination and lactamization. On the other hand, the minor products 
11 result from a Michael addition of 1 onto 4 via the NH2 group and subsequent HCN 
elimination and cyclization. The structures of the products have been established by X-
ray crystallography. 
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1. Introduction. – The importance of 3-amino-5-arylpyrazoles 1 as valuable 
building blocks for the synthesis of various fused heterocycles is well documented in 
original articles [1] as well as in patents [2]. In addition, modifications of the structure 
at the NH2 group were performed in many instances to obtain biologically active 
products [1c][3]. In some cases, aminopyrazoles 1 were used as Michael donors in 
reactions with substrates such as tetracyanoethene (TCNE) [1h] or 
benzylidenemalononitrile derivative [1e]. In both cases, the reaction was initiated by the 
attack of the NH2-group onto the electron deficient C=C bond, and an analogous 
addition/elimination/cyclization mechanism led to pyrazole[2,3-a]pyrimidine 
derivatives 2 and 3, respectively (Scheme 1). 
 
Scheme 1 
 
In a series of recent publications we reported on reactions of electron-deficient 
dialkyl dicyanofumarates 4 with amines [4], diamines [5], and ² -amino alcohols [6]. 
Whereas, in the case of primary and secondary amines, enamines were formed as (Z)- 
and (E)-isomers, respectively, via an addition/elimination sequence, the reactions with 
1,2-diamines yielded cyclic products after subsequent lactamization of the intermediate 
amino ester. For example, (S)-prolinamine (5) reacted smoothly with 4a (R = Me) to 
give the bicyclic product 6 [5] (Scheme 2). Heating of β-amino alcohols with 4a led to 
morpholin-2-one derivatives 7. In this case, the stepwise reaction terminated by 
lactonization [6]. 
 
Scheme 2 
 
 4 
Finally, reactions of 4 with 3-phenyl-1-azabicyclo[1.1.0]butane (8) occurred at 
room temperature yielding a 3:1 mixture of cis- and trans-1-azabicyclo[1.1.1]pentane-
2,3-dicarboxylates 9 [7]. 
The goal of the present study was to examine the reaction of 4 with selected 3-
amino-5-arylpyrazoles 1 as reaction partners possessing four potential nucleophilic 
centers. Previously, the structures of 1 were studied by means of different techniques 
and tautomeric equilibria of 1 both in solution and in the solid state have been discussed 
[8]. The presence of different tautomeric forms of 1 in solution may result in their 
ambivalent reactivity towards electrophilic reagents such as Michael acceptors.  
 
2. Results and Discussion. – Reactions of equimolar amounts of 1 and 4 were 
carried out in boiling 1,2-dichloroethane (method A), in dimethylformamide (DMF) at 
room temperature (method B), or in DMF at 100° (method C). Using method A, the 
progress of the reaction was monitored by TLC, which showed that the conversion of 
the starting materials was complete after 2 h. The 1H-NMR control of the crude mixture 
obtained after evaporation of the solvent evidenced the presence of two products 
containing one and two ester groups, respectively. In all cases, the monoester was the 
major component, which could easily be separated by trituration of the mixture with 
MeOH or acetone and subsequent filtration of the precipitate. The minor products 
obtained from the reactions of 4 with 3-amino-5-(4-methylphenyl)pyrazole (1a), 
containing two ester groups (1H-NMR),  were isolated after chromatographic separation 
(PLC) of the mother liquors obtained after filtration of the major component. 
Alternatively, when DMF was employed using methods B or C, the obtained mixtures 
were diluted with H2O, and the products precipitated thereby were filtered and found to 
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be identical with the major component of the reaction performed in 1,2-dichloroethane 
solution (method A).  
The structure of the major product 10a obtained in the experiment with 1a and 
4a (R = Me) in boiling 1,2-dichloroethane solution (method A) was proposed on the 
basis of the spectroscopic data. The 1H-NMR spectrum ((D6)DMSO) revealed the 
presence of only one MeO group, but no signal of H-C(4) of the pyrazole ring was 
observed. In the 13C-NMR spectrum ((D6)DMSO), signals characteristic for MeO (53.3 
ppm), CN (115.0 ppm), and two C=O groups (160.2, 163.7 ppm) were registered. All 
signals for the other sp2-C atoms appeared between 100 and 150 ppm with low 
intensities and broadening. The presence of the CaN group as well as an ester and an 
amide C=O group was confirmed by strong IR-absorption bands (KBr) located at 2229, 
1740, and 1659 cm–1. The molecular mass m/z 308 corresponded to the formula 
C16H12N4O3, which corresponds with a product formed after elimination of HCN and 
MeOH. 
For the elucidation of the structure of the isolated products, different reaction 
pathways presented in Scheme 3 can be postulated. As mentioned in the introduction, 3-
aminopyrazoles 1 are expected to react as multivalent reagents. Based on the published 
reactions [1e][1h], one could expect a nucleophilic addition of the NH2 group of 1 to 4, 
followed by elimination of HCN to give the ‘enamine-type’ product A. This 
intermediate could undergo cyclizations with one of the ester groups leading, after 
elimination of MeOH, to the six-membered rings B or C via C- or N-nucleophilic 
attack, respectively. Structure C can be eliminated, as the collected data do not confirm 
the presence of a pyrazole H-C fragment. In contrast to C, structure B can be considered 
as a likely product of the reaction. On the other hand, an alternative reaction pathway 
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via C-nucleophilic addition of 1 to 4 would lead to intermediate D, which subsequently 
could undergo lactamization to give the pyrazolo[3,4-b]pyridine-2-one derivative 10.  
 
Scheme 3 
 
Table 1. Reactions of 1 with Dialkyl Dicyanofumarates 4 
a) Method A: Boiling ClCH2CH2Cl, 2 h; method B: DMF, r.t., 16 h; method C: 
DMF, 100°, 11 h 
 
The spectroscopic data presented above did not allow structures B and 10 to be 
distinguished. For this reason, X-ray crystal-structure determinations of the analogous 
products 10d and 10k, obtained from the reactions of 1b and 1d, respectively, with 4a, 
were performed and proved the structures 10d and 10k unambiguously (Fig. 1). It has to 
be mentioned that the two structures in the crystals represent two different tautomers, as 
in 10d the H-atom is located on N(7) whereas it is on N(6) in 10k. 
 
a) b) 
 
Fig. 1. ORTEP-Plots [9] of the molecular structures of a) 10d and b) one of the 
disordered conformations of 10k (CF3 disorder; 50% probability ellipsoids; arbitrary 
numbering of the atoms) 
 
Analogous compounds of type 10 were obtained as major products of the 
reactions of 1a–1d with 4a–4c (Table 1, methods A–C). In the reactions of 1a with 4a–
4c, the mother liquors obtained after filtration of the major products 10a–10c were 
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worked up by preparative TLC, and the minor products 11 were isolated as less polar 
materials1). In all cases, the NMR spectra indicated the presence of two ester groups and 
H–C(4) of the pyrazole ring. Furthermore, strong IR absorptions at ca. 1750 and 1685 
cm–1 correspond well with those observed for enamines obtained from reactions of 4 
with primary amines [4]. In addition, in the case of 11a, a strong absorption at 3115 cm–
1 could be attributed to a NH2 group.  As a matter of fact, the absence of the absorption 
signal of the CN group in the 13C-NMR spectrum of this product suggested that CN 
present in the intermediate A was converted by heterocyclization into the C–NH2 
function. These data suggested that this product was formed via the competitive reaction 
of the NH2 group of 1 with 4 (Scheme 3). In analogy to the described reaction pathway 
with TCNE [1h], this initial step led to the formation of intermediate A, which 
subsequently underwent heterocyclization by nucleophilic attack of the pyrazole N-
atom onto the CN group resulting in the formation of a pyrazolo[2,3-a]pyrimidine 
derivative of type 11. Apparently, in the intermediate A, the two ester groups are cis-
oriented (E-configuration), because this orientation is necessary for the cyclization to 
give 11. Finally, an X-ray crystal-structure determination was carried out in the case of 
11c, which proved the structure of the pyrazolo[2,3-a]pyrimidine (Scheme 3, Fig. 2). 
 
Fig. 2. ORTEP-Plot [9] of the molecular structure of 11c (50% probability 
ellipsoids; arbitrary numbering of the atoms) 
 
                                                          
1) The ratio of products 10a and 11a did not change when heating of the reaction 
mixture was extended to 5 h. In an additional experiment, a sample of 11a was heated in 
boiling dichloroethane in the presence of a catalytic amount of p-TsOH. Even after 3 h, 
unchanged starting material was recovered quantitatively. 
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3. Conclusions. – In contrast to typical aliphatic and aromatic primary amines, 
3-amino-5-arylpyrazoles 1 react as ambivalent reagents with dicyanofumarates 4, 
preferentially as C-nucleophiles, and the formed intermediates of type D smoothly 
undergo lactamization to yield pyrazolo[3,4-b]pyridin-2-ones 10 in a selective manner. 
The competitive Michael addition of the NH2 group of 1 onto 4 and subsequent 
heterocylization via N-nucleophilic attack onto the CN group results in the formation of 
11. Whereas reactions of 1 via the NH2 group are common, the reaction initiated by the 
predominant C-nucleophilic attack is observed rarely [10]. It is especially worth 
mentioning that the reactions of 1 with 4 occur differently than the reported reactions 
with tetracyanoethene, in which the only reported products are formed via initial N-
nucleophilic attack exclusively [1h]. 
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Experimental Part 
 
1. General. M.p.: MEL-TEMP. II (Aldrich); uncorrected. IR Spectra: NEXUS 
FT-IR instrument; in KBr or as film; absorptions in cm–1. 1H-NMR and 13C-NMR 
Spectra: BRUKER AVANCE III instrument (1H at 600 and 13C at 150 MHz) using 
solvent signals as reference; in CDCl3 or (D6)DMSO; chemical shifts (´ ) in ppm; 
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coupling constants J in Hz. The majority of the 13C signals were assigned with the aid of 
DEPT spectra. HR-ESI-MS: Bruker maXis spectrometer.  
2. Starting Materials. 3-Amino-5-arylpyrazoles 1a–d were prepared starting 
with 3-aryl-3-oxopropanenitrile and NH2NH2‡H2O, based on known protocols [11]. 
Dialkyl dicyanofumarates 4a–c were obtained from the corresponding alkyl 
cyanoacetates by reaction with SOCl2 [12]. The SOCl2 used for this reaction must be of 
‘gold labeled’ quality or freshly purified by distillation over quinoline and linseed oil 
[13]. 1,2-Dichloroethane was used as commercially available and distilled over K2CO3 
prior to the use. N,N-Dimethylformamide (DMF) was used as a commercial solvent 
without additional purification.    
3. Reactions of 3-Amino-5-arylpyrazoles 1 with Dialkyl Dicyanofumarates 4. 
Method A:  A soln. of the corresponding 3-aminopyrazole 1 (1 mmol) and dialkyl 
dicyanofumarate 4 (1 mmol) in 1,2-dichloroethane (2 ml) was heated at reflux. The 
progress of the reaction was monitored by TLC, and in all cases complete conversion of 
1 was evidenced after 2 h. Then, the solvent was evaporated and the obtained residue 
was triturated with a small amount of MeOH. After 1 h at r.t., the precipitated yellowish 
major product 10 was filtered and additionally purified by recrystallization from EtOH. 
The mother liquor collected after filtration of 10 was evaporated and separated by prep. 
TLC (silica gel, CH2Cl2/MeOH 99:1). After repeated development, the minor products 
11 were isolated as a less polar fraction (Rf ca. 0.80), and a small amount of 10 was also 
separated as a more polar fraction (Rf ca. 0.15). Products 11 were purified by 
crystallization from MeOH/CH2Cl2 and the combined portions of 10 were obtained as 
analytically pure samples after recrystallization from alcoholic solutions. 
Method B: A soln. containing corresponding 3-aminopyrazole 1 (1 mmol)  and 
an equimolar amount of dialkyl dicyanofumarate 4 in DMF (2 ml) was placed in a 
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closed 25 ml round bottomed flask and kept at r.t. overnight. Then, H2O (10 ml) was 
added and the formed suspension was magnetically stirred at r.t. for ca. 1 h. The 
precipitated yellowish solid was separated by filtration using a paper filter, dried, and 
additionally purified by recrystallization from an alcoholic solution. In this procedure, 
the mother liquor obtained after filtration of 10 was not analyzed and no additional 
work-up was carried out. In the 1H-NMR spectra of the crude products 10, trace 
amounts of products 11 were also observed.  After recrystallization from an alcoholic 
solution, products 10 were obtained as analytically pure samples. 
Method C: Analogous to method B, but the DMF-soln. was heated to 100° for 4 
to 11 h. 
Methyl 3-Cyano-2,7-dihydro-5-(4-methylphenyl)-2-oxo-1H-pyrazolo[3,4-
b]pyridine-4-carboxylate (10a): Yield: 230 mg (75%; method A), and 278 mg (90%; 
method B). Yellow crystals. M.p. 308–312º (decomp., EtOH). IR (KBr): 3365–2926vs 
(br., NH), 2229m (CN), 1740s (C=O), 1659vs (br., C=O), 1608m, 1513m, 1466m, 
1364m, 1252s, 1132w, 1012w, 823m, 674m, 559m. 1H-NMR ((D6)DMSO): 2.37 (s, 
Me); 3.47 (s, MeO); 7.29, 7.36 (AB, JAB = 7.9, 4 arom. H); 12.83, 14.11 (2 br. s, 2 NH). 
13C-NMR ((D6)DMSO): 21.2 (Me); 53.3 (MeO); 115.0 (CN); 128.5, 129.7 (4 arom. 
CH); 100.0, 125.1, 140.0, 141.6, 146.3, 150.2 (6 signals for 7 sp2 C); 160.2 (br.), 163.7 
(2 C=O). HR-ESI-MS: 331.08008 ([M+Na]+,  C16H12N4NaO3; calc.  331.08016). 
Dimethyl 4-Amino-7-(4-methylphenyl)pyrazolo[2,3-a]pyrimidine-2,3-
dicarboxylate (11a). Yield: 32 mg (10%; method A). Colorless crystals. M.p. 258–260º 
(hexane/CH2Cl2). IR (KBr): 3415s (br., NH), 3314s (NH2), 2951w, 1755s (C=O), 1684s 
(C=O), 1632s , 1611m, 1591s, 1570m, 1539w, 1453m, 1437m, 1326s, 1313m, 1241s, 
1213m, 1092w, 1029w, 802s, 621m. 1H-NMR (CDCl3): 2.40 (s, Me); 3.89, 3.97 (2s, 2 
MeO); 6.83 (s, H–C(8)); 7.18 (br. s, NH); 7.27, 7.85 (AB, JAB = 8.0, 4 arom. H); 8.58 
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(br. s, NH). 13C-NMR (CDCl3): 21.4 (Me); 52.3, 52.9 (2 MeO); 95.9 (C(8)-pyrazole); 
126.6, 129.5 (4 arom. CH); 88.7, 129.1, 139.8, 147.9, 149.4, 152.4, 158.1 (7 signals for 
7 sp2 C); 165.9, 166.8 (2 C=O). HR-ESI-MS: 363.10674 ([M+Na]+, C17H16N4NaO4; 
calc. 363.10638).  
Ethyl 3-Cyano-2,7-dihydro-5-(4-methylphenyl)-2-oxo-1H-pyrazolo[3,4-
b]pyridine-4-carboxylate (10b): Yield: 260 mg (81%; method A), and 295 mg (91%; 
method B). Yellowish powder. M.p. 290–294º (decomp., MeOH). IR (KBr): 3382–
2803vs (br., NH), 2228m (CN), 1739s (C=O), 1663vs (br., C=O), 1617m, 1512s, 1467s, 
1375m, 1352w, 1243vs, 1188m, 1018m, 823m, 719w, 683w, 557m. 1H-NMR 
((D6)DMSO): 0.89 (t, J = 7.2, MeCH2); 2.37 (s, MeCAr); 3.95 (q, J = 7.2, MeCH2); 7.18, 
7.36 (AB, JAB = 8.0, 4 arom. H); 12.82, 14.13 (2 br. s, 2 NH). 
13C-NMR ((D6)DMSO): 
13.2 (MeCH2); 21.1 (MeCAr); 63.0 (MeCH2); 114.8 (CN); 128.4, 129.2 (4 arom. CH); 
99.2, 124.9, 140.0, 141.3, 146.5, 150.4 (6 signals for 7 sp2 C); 159.9 (br), 163.0 (2 
C=O). HR-ESI-MS: 345.09599 ([M+Na]+, C17H14N4NaO3; calc. 345.09581). 
Diethyl 4-Amino-7-(4-methylphenyl)pyrazolo[2,3-a]pyrimidine-2,3-
dicarboxylate (11b). Yield: 50 mg (13%) (method A). Colorless crystals. M.p. 218–220º 
(hexane/CH2Cl2). IR (KBr): 3382s (br., NH), 3287s (br., NH2), 2987w, 2975w, 1741s 
(C=O), 1683s (C=O), 1635s, 1595s, 1569m, 1540w, 1453w, 1393w, 1318s, 1236vs, 
1213m, 1087m, 1025w, 799m. 1H-NMR (CDCl3): 1.35, 1.43 (2t, J = 7.2, 2MeCH2); 2.40 
(s, MeCAr); 4.35, 4.43 (2q, J = 7.2, 2MeCH2); 6.83 (s, H–C(8)); 7.19 (br. s, NH); 7.28, 
7.86 (AB, JAB = 8.1, 4 arom. H); 8.70 (br. s, NH). 
13C-NMR (CDCl3): 14.0, 14.1 (2 
MeCH2); 21.3 (MeCAr); 61.4, 62.1 (2 MeCH2); 95.6 (C(8)); 126.5, 129.5 (4 arom. CH); 
87.8, 129.1, 139.7, 147.9, 149.5, 152.6, 157.9 (7 signals for 7 sp2 C); 165.7, 166.4 (2 
C=O). HR-ESI-MS: 391.13812 ([M+Na]+,  C19H20N4NaO4; calc. 391.13768). 
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Isopropyl 3-Cyano-2,7-dihydro-5-(4-methylphenyl)-2-oxo-1H-pyrazolo[3,4-
b]pyridine-4-carboxylate (10c): Yield: 222 mg (66%; method A), and 260 mg (77%; 
method B). Yellow powder. M.p. 254–257º (decomp., MeOH).  IR (KBr): 3439–2750vs 
(br., NH), 2230m (CN), 1734s (C=O), 1661vs (br., C=O), 1620m, 1513m, 1466m, 
1375m, 1249s, 1102m, 1006m, 847w, 823m, 683w, 557w. 1H-NMR ((D6)DMSO): 1.01 
(d, J = 6.6, Me2CH); 2.37 (s, MeCAr); 4.80–4.82 (m, Me2CH); 7.32–7.35 (m, 4 arom. H); 
12.81, 14.12 (2 br. s, 2 NH). 13C NMR ((D6)DMSO): 20.8 (Me2CH); 21.1 (MeCAr); 71.6 
(Me2CH); 114.8 (CN); 128.5, 129.5 (4 arom. CH); 99.3, 124.8, 140.1, 141.5, 146.9, 
150.4 (6 signals for 7 sp2 C); 160.0 (br.), 162.9 (2 C=O). HR-ESI-MS: 359.11123 
([M+Na]+,  C18H16N4NaO3; calc. 359.11146). 
Diisopropyl 4-Amino-7-(4-methylphenyl)pyrazolo[2,3-a]pyrimidine-2,3-
dicarboxylate (11c). Yield: 41 mg (10%; method A). Colorless crystals. M.p. 162–164º 
(hexane/CH2Cl2). IR (KBr): 3420m (br., NH), 3315m (br., NH2), 2980m, 2934w, 1738s 
(C=O), 1677vs (C=O), 1614m, 1593vs, 1571m, 1455m, 1372m, 1334m, 1313m, 1244s, 
1214m, 1166m, 1105s, 1019m, 798m. 1H-NMR (CDCl3): 1.36 (d, J = 6.0, Me2CH); 1.44 
(d, J = 6.6, Me2CH); 2.40 (s, MeCAr); 5.23–5.28 (m, 2 Me2CH); 6.84 (s, H–C(8)); 7.18 
(br. s, NH); 7.28, 7.86 (AB, JAB = 7.9, 4 arom. H); 8.71 (br. s, NH). 
13C-NMR (CDCl3): 
21.4 (MeCAr); 21.7, 21.8 (2 Me2CH); 69.6, 70.0 (2 Me2CH); 95.5 (C(8)); 126.5, 129.5 (4 
arom. CH); 88.1, 129.2, 139.6, 147.9, 149.5, 152.9, 157.8 (7 signals for 7 sp2 C); 165.3, 
165.9 (2 C=O). HR-ESI-MS: 419.16950 ([M+Na]+,  C21H24N4NaO4,  calc. 419.16898). 
Methyl 3-Cyano-2,7-dihydro-5-phenyl-2-oxo-1H-pyrazolo[3,4-b]pyridine-4-
carboxylate (10d): Yield: 157 mg (53%; method A), and 265 mg (90%; method B). 
Yellowish powder. M.p. 324–330º (decomp., MeOH).  IR (KBr): 3367–2795vs (br., 
NH), 2226m (CN), 1746s (C=O), 1659vs (br., C=O), 1618m, 1545m, 1511s, 1466s, 
1365m, 1247vs, 1138w, 1026s, 866m, 763m, 701m, 669m, 561m. 1H-NMR 
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((D6)DMSO): 3.42 (s, MeO); 7.35–7.45 (m, 2 arom. H); 7.50–7.60 (m, 3 arom. H); 
12.82, 14.12 (2 br. s, 2 NH). 13C-NMR ((D6)DMSO): 53.1 (MeO); 114.8 (CN); 128.5, 
129.0, 129.9 (5 arom. CH);  100.2, 142.1, 145.8, 150.0 (4 signals for 6 sp2 C); 160.2 
(br.), 163.5 (2 C=O). HR-ESI-MS: 317.06468 ([M+Na]+,  C15H10N4NaO3,  calc. 
317.06451). 
Ethyl 3-Cyano-2,7-dihydro-5-phenyl-2-oxo-1H-pyrazolo[3,4-b]pyridine-4-
carboxylate (10e): Yield: 250 mg (81%; method C). Yellow crystals. M.p. 298–302º 
(decomp., EtOH). IR (KBr): 3390–2900vs (br., NH), 2231m (CN), 1740s (C=O), 
1678vs (br., C=O), 1639s, 1565m, 1523w, 1450m, 1344w, 1238vs, 1177m, 1021m, 
910m, 769m, 749m, 648w. 1H-NMR ((D6)DMSO): 0.85 (t, J = 7.2, MeCH2); 3.91 (q, J = 
7.2, MeCH2); 7.43–7.51 (m, 4 arom. H), 12.88, 14.13 (2 br. s, 2 NH). 
13C-NMR 
((D6)DMSO): 13.1 (MeCH2); 62.8 (MeCH2); 114.7 (CN); 128.5, 128.9, 130.0 (5 arom. 
CH); 99.8, 141.1, 146.5, 150.1 (4 signals for 6 sp2 C); 159.8, 163.1 (2 C=O). MS: 308 
(100, M+), 235 (27),149 (51), 77 (43). Anal. calc. for C16H12N4O3 (308.29): C 62.33, H 
3.92, N 18.17; found: C 62.24, H 3.85, N 18.23. 
Isopropyl 3-Cyano-2,7-dihydro-5-phenyl-2-oxo-1H-pyrazolo[3,4-b]pyridine-4-
carboxylate (10f): Yield: 220 mg (68%) (method C). M.p. > 300º (decomp.). 3400–
2900vs (br., NH), 2229m (CN), 1737s (C=O), 1678vs (br., C=O), 1639s, 1564m, 
1508m, 1465m, 1374w, 1241vs, 1179m, 1102m, 1014w, 909m, 830w, 767m, 720m, 
700m, 645w, 567w. 1H-NMR ((D6)DMSO): 0.99 (d, J = 6.6, Me2CH); 4.79 (m, 
Me2CH); 7.45–7.54 (m, 5 arom. H); 12.83, 14.14 (2 br. s, 2 NH). 
13C-NMR 
((D6)DMSO): 20.8 (Me2CH); 71.5 (Me2CH); 114.7 (CN); 128.6, 128.9, 130.0 (5 arom. 
CH); 99.6, 141.5, 146.5, 150.1 (4 signals for 6 sp2 C); 160.1 (br.), 162.8 (2 C=O). MS: 
322 (58, M+), 280 (100), 263 (17), 179 (17), 152 (19), 124 (15), 98 (23),  77 (55).   
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Anal. calc. for C17H14N4O3 (322.32): C 63.35, H 4.38, N 17.38; found: C 63.49, H 4.25, 
N 17.31. 
 
Methyl 3-Cyano-2,7-dihydro-5-(4-chlorophenyl)-2-oxo-1H-pyrazolo[3,4-
b]pyridine-4-carboxylate (10g): Yield: 260 mg (79%) (method C). M.p. 299-306º  
(decomp., MeOH). IR (KBr): 3450–2850vs (br., NH), 2229m (CN), 1737s (C=O), 
1651vs (br., C=O), 1509m, 1364m, 1252s, 1092m, 1014m, 837s, 677m(br.) 1H-NMR 
((D6)DMSO): 3.44 (s, MeO); 7.25, 7.30 (br.) (AB, JAB = 7.9, 4 arom. H).  MS: 328 (37, 
M+), 139 (100), 111 (35), 75 (33.6). Anal. calc. for C15H9ClN4O3 (328.71): C 54.81, H 
2.76, N 17.04; found: C 54.71, H 2.69, N 17.11. 
 
Ethyl 3-Cyano-2,7-dihydro-5-(4-chlorophenyl)-2-oxo-1H-pyrazolo[3,4-
b]pyridine-4-carboxylate (10h): Yield: 230 mg (67%) (method C). M.p. 283-287º 
(decomp., MeOH). IR (KBr): 3382–2800vs (br., NH), 2230w (CN), 1747s (C=O), 
1659vs (br., C=O), 1467s, 1389m, 1253vs, 1092m, 1018m, 835m, 665m. 1H-NMR 
((D6)DMSO): 0.87 (t, J = 7.2, MeCH2); 3.88 (q, J = 7.2, MeCH2); 7.10, 7.28 (br.) (AB, 
JAB = 8.0, 4 arom. H); 12.94, 14.16 (2 br. s, 2 NH). MS: 328 (M
+). Anal. calc. for 
C16H11ClN4O3 (342.74): C 56.07, H 3.23, N 16.35; found: C 56.07, H 3.23, N 16.35. 
 
Isopropyl 3-Cyano-2,7-dihydro-5-(4-chlorophenyl)-2-oxo-1H-pyrazolo[3,4-
b]pyridine-4-carboxylate (10i): Yield: 250 mg (70%) (method C). M.p. > 300º 
(decomp., MeOH). IR (KBr): 3420–2750vs (br., NH), 2229w (CN), 1728s (C=O), 
1659vs (br., C=O), 1381m, 1255m (br.), 1095m, 1008w, 841m, 673m. 1H-NMR 
((D6)DMSO): 0.891.04 (t, J = 7.2, MeCH2); 2.37 (s, MeCAr); 3.954.85 (q, J = 7.2, 
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MeCH2); 7.18, 7.36 (br.) (AB, JAB = 8.0, 4 arom. H). MS: 356 (M
+). Anal. calc. for 
C17H13ClN4O3 (356.76): C 57.23, H 3.67, N 15.70; found: C 57.35, H 3.75, N 15.62. 
 
Methyl 3-Cyano-2,6-dihydro-5-(trifluoromethyl)phenyl-2-oxo-1H-pyrazolo[3,4-
b]pyridine-4-carboxylate (10k): Yield: 140 mg (38%; method A). M.p. 271–280º 
(decomp., MeOH).  IR (KBr): 3200–2750vs (br., NH), 2247s (CN), 1736s (C=O), 1656s 
(br., C=O), 1622m, 1607s, 1501s, 1464m, 1411m, 1362w, 1328vs, 1258vs, 1137s (br.), 
1068s, 1006m, 850m, 730w, 686m, 604w (br.), 560w. 1H-NMR ((D6)DMSO): 3.46 (s, 
MeO); 7.64, 7.92 (AB, JAB = 8.4, 4 arom. H); 12.80, 14.15 (2 br. s, 2 NH). 
13C-NMR 
((D6)DMSO): 53.1 (MeO); 114.8 (CN); 125.8, 129.4 (4 arom. CH); 121.5, 126.9, 134.1, 
142.0, 144.6, 149.9 (6 sp2 C); 124.2 (d, 1JC,F = 270.8, CF3); 129.8 (d, 
2JC,F = 32.0, C–
CF3); 160.8, 163.5 (2 C=O).  HR-ESI-MS: 385.0516 ([M+Na]
+,  C16H9F3N4NaO3; calc. 
385.0524). 
7. X-Ray Crystal-Structure Determination of 10b, 10k, and 11c (Table 2 and 
Figs. 1 and 2)2). The measurements of 10k and 11c were performed on an Agilent 
Technologies SuperNova area-detector diffractometer [14] using CuKα radiation (λ 
1.54184 Å) from a micro-focus X-ray source and an Oxford Instruments Cryojet XL 
cooler, whereas those of 10b were performed on a Nonius KappaCCD area-detector 
diffractometer [15] using graphite-monochromated MoKα radiation (λ 0.71073 Å). Data 
reduction was performed with CrysAlisPro [14] (10k, 11c) and HKL Denzo and 
Scalepack [16] (10b), respectively. The intensities were corrected for Lorentz and 
polarization effects, and an empirical absorption correction using spherical harmonics 
                                                          
2) CCDC-913237–913239. contain the supplementary crystallographic data for this 
paper. These data can be obtained free of charge from the Cambridge 
Crystallographic Data Centre via http://www.ccdc.cam.ac.uk/data_request/cif. 
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[14] was applied in the cases of 10k and 11c. Equivalent reflections were merged. The 
data collection and refinement parameters are given in Table 2, and views of the 
molecules are shown in Figs. 1 and 2. The structures were solved by direct methods 
using SHELXS97 [17] (10k and 11c) or SIR92 [18] (10b), which revealed the positions 
of most non-H-atoms. In the case of 10k, the F-atoms of the CF3 group are disordered 
over two orientations. Two sets of positions were defined for these F-atoms and the site 
occupation factor of the major orientation of the CF3 group refined to 0.893(3).  
Similarity restraints were applied to the chemically equivalent C–F and F·· ·F distances, 
while neighboring atoms within and between each conformation of the disordered CF3 
group were restrained to have similar atomic displacement parameters. In all cases, the 
non-H-atoms were refined anisotropically. The amine H-atoms of 10k and 11c were 
placed in the positions indicated by a difference electron density map and their positions 
were allowed to refine together with individual isotropic displacement parameters. All 
remaining H-atoms in all structures were placed in geometrically calculated positions 
and refined by using a riding model where each H-atom was assigned a fixed isotropic 
displacement parameter with a value equal to 1.2 Ueq of its parent atom (1.5 Ueq for Me 
groups). The refinement of each structure was carried out on F2 by using full-matrix 
least-squares procedures, which minimized the function Σw(Fo2 – Fc2)2. In the cases of 
10b and 11c, a correction for secondary extinction was applied. Neutral atom scattering 
factors for non-H-atoms were taken from [19a], and the scattering factors for H-atoms 
were taken from [20]. Anomalous dispersion effects were included in Fc [21]; the values 
for f ' and f " were those of [19b]. The values of the mass attenuation coefficients are 
those of [19c]. All calculations were performed using the SHELXL97 [17] program. 
 
Table 2. Crystallographic Data for Compounds 10d, 10k, and 11c 
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Legends 
 
Table 1. Reactions of 1 with Dialkyl Dicyanofumarates 4 
 
Table 2.  Crystallographic Data for Compounds 10d, 10k, and 11c  
 
Fig. 1. ORTEP-Plots [9] of the molecular structures of a) 10d and b) one of the 
disoerdered conformations of 10k (CF3 disorder; 50% probability ellipsoids; arbitrary 
numbering of the atoms) 
 
Fig. 2. ORTEP-Plot [9] of the molecular structure of 11c (50% probability ellipsoids; 
arbitrary numbering of the atoms) 
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Table 1. Reactions of 1 with Dialkyl Dicyanofumarates 4 
_______________________________________________________________________ 
 
1 (Ar) 4 (R) Reaction  10 (Yield [%]) 11 (Yield [%]) 
  conditionsa) 
_______________________________________________________________________ 
 
a (4-MeC6H4) a (Me) A; B a (75; 90) a (10; 0) 
 b (Et) A; B b (81; 91) b (13; 0) 
 c (iPr) A; B c (66; 77) c (10; 0) 
b (Ph) a (Me) A; B d (53; 90)  
 b (Et) C e (81) 
 c (iPr) C f (68) 
c (4-Cl-C6H4) a (Me) C g (79) 
 b (Et) C h (67) 
 c (iPr) C i (70) 
d (4-CF3C6H4) a (Me) A k (38) 
______________________________________________________________________ 
 
a) Method A: Boiling ClCH2CH2Cl, 2 h; method B: DMF, r.t., 16 h; method C: DMF, 
100°, 11 h 
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Table 2.  Crystallographic Data for Compounds 10d, 10k, and 11c  
__________________________________________________________________________________ 
  
 10d 10k  11c 
__________________________________________________________________________________ 
Crystallized from MeOH MeOH Hexane/CH2Cl2 
Empirical formula C15H10N4O3 C16H9F3N4O3 C21H24N4O4  
Formula weight [g mol-1] 294.27 362.27 396.44  
Crystal color, habit colorless, prism yellow, prism colorless, plate  
Crystal dimensions [mm] unknown 0.15 × 0.20 × 0.20 0.07 × 0.12 × 0.28 
Temperature [K] 298(1) 160(1) 160(1)  
Crystal system monoclinic monoclinic triclinic  
Space group P21/c P21/c P
_
,1  
Z 4 4  2 
Reflections for cell determination 2852 4986  26596  
2θ range for cell determination [°] 5–55 6 – 142 6 – 149  
Unit cell parameters a [Å] 12.6815(4) 11.1763(4) 8.47828(19) 
 b [Å] 8.7276(4) 9.8855(2) 9.5942(2) 
 c [Å] 13.5654(6) 15.2144(6) 14.1580(3) 
 α [°] 90 90 96.3610(17)  
 β [°] 115.463(4) 111.113(4) 100.4022(17) 
 γ [°] 90 90 115.294(2)  
 V [Å3] 1355.6(1) 1568.10(9) 1000.99(4) 
Dx [g cm-3] 1.442 1.534 1.315  
Radiation MoKα CuKα CuKα 
µ [mm-1] 0.1046 1.160 0.762  
 24 
Scan type ω ω ω  
2θ(max) [°] 55 142.2 148.8  
Transmission factors (min; max) - 0.464; 1.000 0.033; 1.000 
Total reflections measured 5409 13798 37503  
Symmetry independent reflections 3047 2966 4038  
Reflections with I > 2σ(I) 1187 2443 3739  
Reflections used in refinement 3047 2966 4038  
Parameters refined; restraints 201; 0 272; 66 276; 0  
Final R(F) [I > 2σ(I) reflections] 0.0566 0.0570 0.0364  
 wR(F2) (all data) 0.1211 0.1625 0.1022  
Weighting parameters [a; b]a)  0.0416; 0 0.0750; 1.7522 0.0525; 0.2666  
Goodness of fit 0.915 1.055 1.052  
Secondary extinction coefficient 0.028(4) - 0.0159(9) 
Final ∆max/σ 0.001 0.001 0.001 
∆ρ (max; min) [e Å-3] 0.16; –0.17 0.40; –0.48 0.28; –0.19 
 
a) w–1 = σ2(Fo2) + (aP)2 + bP where P = (Fo2 + 2Fc2)/3 
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